191092-08-7

Usage

Uses

Used in Pharmaceutical Synthesis:
(R)-3-(Tosyloxymethyl)-N-Boc-piperidine is used as a key intermediate in the synthesis of various pharmaceuticals, due to its ability to be incorporated into a wide array of biologically active compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, (R)-3-(Tosyloxymethyl)-N-Boc-piperidine is utilized as a building block for the creation of compounds with pesticidal, herbicidal, or fungicidal properties, contributing to the development of more effective and targeted agrochemicals.
Used in Chiral Ligand and Catalyst Preparation:
(R)-3-(Tosyloxymethyl)-N-Boc-piperidine is also employed as a component in the preparation of chiral ligands and catalysts, which are essential for asymmetric synthesis. These chiral catalysts and ligands play a critical role in the production of enantiomerically pure compounds, which are often necessary for the desired biological activity of pharmaceuticals.
Organic Synthesis:
Within the broader field of organic synthesis, (R)-3-(Tosyloxymethyl)-N-Boc-piperidine is used as a versatile intermediate for the preparation of a variety of complex organic molecules, showcasing its utility in chemical research and development.

Upstream product

• 191599-51-6 ethyl (S)-1-[(tert-butoxy)carbonyl]piperidine-3-carboxylate 
• 37675-18-6 (S)-(+)-nipecotic acid ethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 140695-84-7 tert-butyl (3S)-3-(hydroxymethyl)piperidine-1-carboxylate 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 278788-75-3 C₁₅H₂₅N₃O₂ 
• 140645-22-3 (3S)-3-azidomethyl-1-(tert-butoxycarbonyl)-piperidine 
• 140645-23-4 1,1-dimethylethyl (3R)-3-(aminomethyl)-1-piperidinecarboxylate 

Relevant academic research and scientific papers

BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY

Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand that binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Novel Triazolopyrazine Derivatives and Use Thereof

The present invention relates to novel triazolopyrazine derivatives or a pharmaceutically acceptable salt, and a pharmaceutical composition for inhibiting c-Met tyrosine kinase activity and a pharmaceutical composition for preventing or treating hyperproliferative disorders, containing the same as active ingredients. The present invention effectively inhibits c-Met tyrosine kinase activity, thereby being able to be useful as a drug for various hyperproliferative disorders such as cancers, psoriasis, rheumatoid arthritis, diabetic retinitis, etc. related to excessive cell proliferation and growth by abnormal kinase activation.

NOVEL TRIAZOLOPYRAZINE DERIVATIVE AND USE THEREOF

The present invention relates to a novel triazolopyrazine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating hyper proliferative disorder. The present invention can be useful as a therapeutic agent for various hyper proliferative disorders associated with excessive cell proliferation and growth caused by abnormal kinase activity, such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy, by efficiently inhibiting c-Met tyrosine kinase activity.

Novel Compounds

Compounds of Formulae I, or pharmaceutically acceptable salts thereof: wherein X, R1, R2 and R3 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

FARNESYL PROTEIN TRANSFERASE INHIBITORS

Disclosed are compounds of formula (1.0), wherein R represents a cyclic moiety to which is bound an imodazolylalkyl group; R represents a carbamate, urea, amide or sulfonamide group; and the remaining substituents are as defined herein. Also disclosed is a method of treating cancer and a method of inhibiting farnesyl protein transferase using the disclosed compounds.

Novel farnesyl protein transferase inhibitors as antitumor agents

Disclosed are novel tricyclic compounds represented by the formula (1.0): and a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Novel farnesyl protein transferase inhibitors as antitumor agents

Disclosed are novel tricyclic compounds represented by the formula (1.0): or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.